Latest News & Features
article
In the US, the impact of authorised biologics on biosimilars is post-regulated by the competition authorities, while in Europe, pharmaceutical regulatory authorities consider competition impacts in addition to post-regulation by the competition authorities. 16 June 2022
Big Pharma
BMS unit Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have urged the US Supreme Court to reinstate their $1.2 billion win in a patent clash with Kite Pharma, a subsidiary of Gilead. 16 June 2022
article
The World Trade Organization has issued draft texts relating to its IP response to the COVID-19. 14 June 2022
article
Baxalta, a subsidiary of Japan-headquartered pharmaceutical company Takeda, has asked the US Court of Appeals for the Federal Circuit to overturn a decision that invalidated its antibody patent. 14 June 2022
Big Pharma
Israel-headquartered Teva has settled its dispute with Indian generic maker Aurobindo over a drug used to treat Huntington’s disease. 13 June 2022
Americas
Novartis Pharmaceuticals and the Dana-Farber Cancer Institute have filed two lawsuits to bar generic versions of leukaemia drug, Rydapt. 9 June 2022
Americas
A bipartisan group of six US senators have asked the US Patent and Trademark Office to address ‘patent thickets’, a tactic that pharmaceutical companies allegedly use to stifle competition. 9 June 2022
Generics
Pfizer has sued MSN Laboratories to prevent the rollout of generic copies of the blockbuster drug Xeljanz, used to treat patients with arthritis. 9 June 2022
Big Pharma
Moderna’s bid to avoid a COVID-19 patent claim has been rejected by two pharma companies that are suing the vaccine manufacturer for infringing its drug delivery technology. 7 June 2022
Big Pharma
A judge at the US District Court for the Northern District of California has granted a motion for preliminary approval of a $10.8 million settlement in an antitrust suit. 7 June 2022